LEADER 01316nam0 22003133i 450 
001 VAN00130355
005 20240806100831.340
017 70$2N$a978-3-319-75836-7
100   $a20200729d2018       |0itac50      ba
101   $aeng
102   $aCH
105   $a||||    |||||
200 1 $aTargeting the DNA Damage Response for Anti-Cancer Therapy$fJohn Pollard, Nicola Curtin editors
210   $aCham$cSpringer$d2018
215   $aix, 401 p.$d24 cm
410  1$1001VAN00111323$12001 $aCancer Drug Discovery and Development$1210  $aNew York$cSpringer
620   $aCH$dCham$3VANL001889
702  1$aCurtin$bNicola$3VANV103858
702  1$aPollard$bJohn$3VANV103857
712   $aHumana <editore>$3VANV108434$4650
712   $aSpringer <editore>$3VANV108073$4650
801   $aIT$bSOL$c20240906$gRICA
856 4 $uhttps://link.springer.com/book/10.1007/978-3-319-75836-7$zE-book ? Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth
899   $aBIBLIOTECA CENTRO DI SERVIZIO SBA$2VAN15
912   $fN
912   $aVAN00130355
950   $aBIBLIOTECA CENTRO DI SERVIZIO SBA$d15CONS      SBA EBOOK 6741                      $e15EB 6741              20200729            
996   $aTargeting the DNA Damage Response for Anti-Cancer Therapy$91754035
997   $aUNICAMPANIA